Cognitive Enhancement Among Medical Students

Cognitive-Enhancement Drug Use Among Future Physicians: Findings From A Multi-Institutional Census of Medical Students

Robyn M. Emanuel, M.D., MPH, Sandra Frellsen, MD, FACP, Kathleen Kashima, PhD, Sandra M. Sanguino, MD, MPH, Frederick S. Sierles, MD; Cathy J. Lazarus, MD, FACP

1 Dr. Emanuel was a medical student at Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL when this work was done. She is currently a first year Internal Medicine Resident at Mayo Clinic-Scottsdale,

2 Dr. Frellsen is the Co-Director of Medical Student Programs, Dept. of Medicine at Rush Medical College, Rush University, Chicago, IL,

3 Dr. Kashima is Senior Associate Dean of Students at the University of Illinois College of Medicine, Chicago, IL

4 Dr. Sanguino is Associate Dean of Student Programs and Career Development at Northwestern University, Feinberg School of Medicine, Chicago, IL,

4 Dr. Sierles is a Professor and Director of Medical Student Education in the Department of Psychiatry and Behavioral Sciences, Rosalind Franklin University of Medicine and Science, North Chicago, IL.

6 Dr. Lazarus is the Chief of Workforce Development Service at the Southeast Louisiana Veterans Healthcare System and Professor of Medicine at Tulane University School of Medicine, in New Orleans, LA. She was previously the Sr. Associate Dean for Student Affairs

1
EMANUEL, et. al.                                      Cognitive Enhancement Among Medical Students

and Medical Education at Rosalind Franklin University of Medicine and Science, North Chicago, IL.

**Corresponding author:**

Cathy J. Lazarus, M.D., FACP
Professor of Medicine
Tulane University School of Medicine
Chief, Workforce Development Service
Southeast Louisiana Veterans Health Care System
P.O. Box 61011
New Orleans, LA 70161
Telephone: 504-566-8401
E-mail: clazaru@tulane.edu

The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government. Funding for this project was provided through an educational development fund at Rosalind Franklin University of Medicine and Science.

Article word count= 3,000 ; Abstract = 247; Figures=2; Tables=4; References= 32,

**Keywords:** Cognitive enhancement, nootropics, amphetamine salts, methylphenidate, medical students, drug use
Abstract

**Background:** Nonmedical use of prescription psychostimulants such as methylphenidate and amphetamine salts for the purpose of cognitive-enhancement is a growing trend, particularly in educational environments. To our knowledge, no recent studies have evaluated the use of these psychostimulants in a medical academic setting.

**Objective:** To conduct an online census of psychostimulant use among medical students

**Design:** In 2011, we conducted a multi-institutional census using a 31-48 item online survey regarding use of prescription psychostimulants.

**Participants:** 2,732 actively enrolled medical students at four private and public medical schools in the greater Chicago area

**Main Measures:** Prevalence and correlates of psychostimulant use

**Key Results:** 1,115 (41%) of students responded to the web-based questionnaire (range 26-47% among schools). On average, students were 25.1 years of age (SD= 2.7, range 20-49), and single (70%). Overall, 18% (198/1,115) of this medical student sample had used prescription psychostimulants at least once in their lifetime with first use most often in college. Of these, 11% (117/1,115) of students reported use during medical school (range 7-16% among schools). Psychostimulant use was significantly correlated with use of barbiturates, ecstasy, and tranquilizers (Pearson’s correlation r>0.5, Student’s t-test p<0.01); male gender (21% male versus 15% female, Chi squared p=0.007); and training at a medical school which by student self-report determined class rank (68% versus 51%, Chi-squared p=0.018). Non-users were more likely to be first year students (Chi-squared p=0.048) or to have grown up outside of the United States (Chi-squared p=0.013).
Conclusions. Use of psychostimulants, including for non prescribed purposes, is common among medical students. Further study of the implications and consequences, as well as use among residents and practicing physicians is needed to inform evidence-based policy.
Introduction

Nonmedical use of prescription stimulants to enhance cognitive function in healthy adults has drawn national attention from policy makers, educators, researchers, and the general public. There is evidence of the memory- and attention-boosting properties of prescription stimulants and expanding popularity\(^1\) of these drugs among educated young adult populations. Ethical debate surrounds the use cognitive-enhancing substances, also called nootropics, among the healthy.\(^2\) Recent reviews have identified prescription psychostimulant use as a growing problem in modern prescription drug abuse, with a 5-35\% of college students using prescription psychostimulants for non-medically prescribed purposes,\(^3\) and a high proportion of children and young adults obtaining these drugs from off-market sources.\(^4\)

Prescription psychostimulants are frequently prescribed to treat attention deficit hyperactivity disorder among children, attention deficit disorder (ADD) among adults, narcolepsy, obesity, fatigue, dementia, and hyperactivity.\(^5,\!^6\) For individuals with reduced self-regulation and motivation and difficulties with distraction, task initiation, multitasking and organization, the symptoms seen in ADD, psychostimulants have been shown to improve functioning in daily roles. Within healthy populations, amphetamines have also been shown to improve short term memory,\(^7,\!^8\) verbal recall,\(^9\) and memory consolidation.\(^10\) However, not all effects of psychostimulants are beneficial. Continued use of psychostimulants can lead to increased tolerance for the drugs and psychological dependence,\(^15\) although the time period required for such dependence has not been adequately characterized.

Because of the high potential for abuse and dependence,\(^11\) psychostimulants are considered controlled substances under the U.S. Controlled Substances Act.\(^12\) Widespread use of cognitive enhancing drugs for non-medically prescribed purposes is a relatively “new” diversion
in the United States. From 1990-99, a two to five-fold increase in the prevalence of methylphenidate prescriptions was observed in the U.S. College students using non-physician directed psychostimulants most often cited non-medical reasons for use, such as to increase concentration (65.2%), assist with studying (59.8%), and increase alertness (29.9%). Given this high rate of illicit use, it is not surprising that access to psychostimulants is frequently through off-market sources. A recent survey indicated that 26% of college students with a prescription for methylphenidate had at least once given or sold some of their medication to others. Thus psychostimulants represent an easily accessible medication that is perceived to improve cognitive performance.

There is much evidence to suggest that medical students in the United States and beyond may be susceptible to medical stimulant use and other drug use. Baldwin et al in a 1991 study found that 87.5% of medical students used alcohol and 10% of medical students smoked marijuana at least once within the previous month. This trend appears to continue into residency, with increasing likelihood of both alcohol and illicit drug use after medical school (50% second year of medical school vs. 65% during first year residency). Recent increases in methylphenidate and amphetamine use among U.S. college students and data suggesting that competitive college environments predict increased stimulant use, lead us to suspect continued stimulant use into medical school and beyond. The June 2009 edition of the Association of American Medical College’s Reporter also highlighted this issue, suggesting that students who used psychostimulants in college are now entering medical schools across the U.S.

Given these trends, unapproved psychostimulant abuse potentially represents a prevalent, uncharacterized issue with major implications for physician competence and conduct. To our knowledge, no recent studies have evaluated this trend of amphetamines, methylphenidate, or
other cognitive-enhancing drugs on U.S. medical school campuses. With this in mind, we
conducted an online survey of medical students about their use of and attitudes towards
stimulant medications.

**Methods:**

We administered an online, anonymous survey about cognitive enhancement drug use
and associated factors to all enrolled students at four Chicago-area medical schools, one public
and three private institutions, henceforth labeled as Schools A through D for institutional
privacy. A team of collaborators designed survey items, similar in style to those used in the
Monitoring the Future Study (University of Michigan, Ann Arbor, MI) REF NEEDED, and
piloted them with ten podiatry students. Sections included demographic profile, substance use
(such as caffeine and other energy enhancers), and psychostimulant use. On average, the survey
took 3 to 7 minutes to complete and comprised 48 questions for individuals who had previously
used amphetamines and 31 questions for non-users. For protection of student anonymity, the
survey did not contain any identifiable data, and a Certificate of Confidentiality was obtained
from the National Institute(s) of Health. No questions were worded in a way that might allow
investigators to identify a particular student’s responses.

All enrolled students at the participating schools were invited to complete the web-based
survey, and all responses were self reported. Between mid-October and December, 2011, each
of the designated study site directors sent an e-mail invitation and three follow-up e-mail
reminders to medical students at their school. E-mail invitations included a brief explanation of
the study; a statement regarding the anonymous nature of survey, which included a summary of
the certificate of confidentiality; and a hyperlink to the online survey website. Students were
requested not to complete the survey a second time if they had already completed it once.
Students were required to complete a modified consent prior to initiating the online survey. The consent form was not linked to the survey itself.

Funding was provided by a educational development fund at School A. Institutional Review Boards at all participating schools approved the study prior to implementation. The Office of Measurement Services (OMS) associated with the University of Minnesota contracted for online hosting of the survey and data analysis. Statistical analyses including frequencies, Chi squared, Pearson’s correlation coefficients, and Student’s t-tests were performed using SPSS.

Results:

Participants: Total medical student enrollment was 750 for School A, 695 for School B, 530 for School C, and 740 for School D. Of the 2,732 eligible students, 41% (1,115) responded to the online questionnaire (range 26-47 % among schools). The mean age of respondents was 25.1 years of age (SD= 2.7, range 20-49) and 70 % were single. Overall, approximately half of all respondents were female (52 %). Respondents represented an equal mix of all class years (25 % first year, 56% female; 28 % second year, 55% female; 24 % third year, 47 % female; 22% fourth year, 51. % female; 0.9% fifth year or beyond, 40 % female). The demographics of the respondents were not significantly different than the overall student enrollment at each school.

Psychostimulant Use: On average, 18% (198/1,115) of respondents had used psychostimulants, such as amphetamines or methylphenidate, at least once in their lifetime (range 13%-26% among schools, not powered to detect significance). Most often students reported their first experience with prescription stimulants in college (57%,108/190), with the next largest proportion of students reporting first use in medical school (22 %,42/190), high school (12 %, 23/190), or other professional or graduate school (3 %,6/190). Of the 198 students who reported ever using psychostimulants, 60% reported use during medical school, indicating
that the overall prevalence of psychostimulant use while in medical school is 11% (117/1,115; range among schools of 4 -17%, nonsignificant). Frequency of prescription stimulant use ranged widely, with 23% of students (18/78) reporting only one use in the previous 30 days, 54% of students (42/78) between 2 and 25 uses in the previous 30 days, 19% of students (15/78) daily use, and 4% of students (3/78) reporting 60 to 90 uses in the previous 30 days. Of stimulant users, the median frequency was 10 to 12 separate occasions in the previous 30 days. Preferred psychostimulant sources were most often amphetamine salts (Adderall©, 75%) or methylphenidate (Ritalin©, Concerta©, Metadate©, and Methylin©; 41%), taken by oral ingestion (92%) and/or inhalation (18%).

**Psychostimulant Acquisition and Reasons for Use:** Non-medically prescribed use of stimulant substances was common, with 63% (123/197) of student users stating that they did not receive their psychostimulant from a physician (Figure 1). Of the students who responded to the question “have you ever given away or sold a psychostimulant that had been prescribed for you” 23% (18/77) of students reported that they had—at least once—done so. When queried on reasons they used psychostimulants, students most often endorsed using psychostimulants to help them study (69%) and to aid with concentration (65%) (Figure 2).

**Correlations with Psychostimulant Use:** Psychostimulant use was significantly correlated with use of other drugs (Table1). Lifetime use of psychostimulants was significantly associated with male gender (21% male versus 15% female, Chi squared p=0.007). Students who mainly grew up outside the United States were significantly less likely to report any lifetime psychostimulant use than their U.S.-reared counterparts (outside of U.S. 4% versus 20% raised in US; Chi squared p=0.013). Overall prevalence of psychostimulant use while in medical school was significantly associated with current year in medical school, with first year students being
least likely to report use compared to their second, third, fourth and fifth-year colleagues (41% first year (n=42), 66% second year (n=59), 60% third year (n=52), 71% fourth year (n=41), 50% fifth year or beyond (n=2); Chi squared  p=0.048). Students who self reported attending a school which determined class rank were significantly more likely to respond that they had used psychostimulants while in medical school (class rank assessed 68% versus no class rank 51%, Chi squared  p=0.018).

**Medical Student Perceptions of Psychostimulant Use:** Half of respondents reported that they perceived “psychostimulant use to enhance academic performance” as problem (50% perceived as problem, 21% did not perceive as problem, 28% didn’t know). 69 % (772) disagreed with the statement “it is okay for medical students to take psychostimulants to enhance academic performance,” 14.2% (158) endorsed the statement as “okay,” and 16.2% (81) were unsure.

Of the 198 students who had used psychostimulants, 95% (187)perceived that some improvement in academic standing could be gained by taking psychostimulants. When asked whether their experience with psychostimulants would impact their desire to prescribe psychostimulants for their patients, 16% (3) said it would make them more likely to prescribe, 23% (44) said it would make them less likely to prescribe, and 61% (119) felt unsure. When asked whether they felt that they would be using psychostimulants five years from now, the majority 68% (133) felt that they probably or definitely will not; 17% (34) felt they probably or definitely will; and 15% (29) were unsure. When compared to students using psychostimulants, non-users were more likely to report perceiving stimulant use to boost academic performance as a problem, [ 53% (481/911) no lifetime use vs. 39% (76/195) at least one lifetime use, nonsignificant].
At the end of the questionnaire, students had the opportunity to provide an open-ended comment. Approximately 10% of respondents chose to do so.

**Discussion:**

To our knowledge, this study is the first investigation of cognitive enhancement drug use among U.S. medical students in over two decades. Our results indicate that on average 11% of all medical students use psychostimulants while in medical school. Many of these students acquire their medications from friends, relatives or classmates, and slightly less than half take these psychoactive substances under the direction of a doctor. These results indicate a relatively high use prevalence among these future physicians.

First year students reported significantly lower rates of prescription stimulant use than their second, third, or fourth year colleagues. This may be due to the timing of the survey, with most medical schools starting the year in August, many first-year students may not have had significant interaction with their classmates to have knowledge of these medications. Our data supports this theory, with 22% of students reporting their first use of these medications in medical school, and an approximately equivalent increase in stimulant use between the first and second year classes (41% first year to 66% in second year). Years with standardized testing (USMLE step 1 and USMLE step 2) had the highest reported use of stimulants.

Medical students are at a unique juncture in their medical and professional endeavors. Their pre-medical career takes place in an intensely competitive academic environment, in which many have adapted methods that ensure academic success, such as the use of cognitive-enhancing medications to supplement study habits. Once students enter medical school, additional stresses to obtain competitive residencies or to maintain high academic performance in an even more competitive environment can reinforce continued drug use by
becoming an additional coping mechanism to tackle academic challenges. This idea is consistent with other literature, which indicates that a highly competitive college environment is predictive of ADD prescription misuse, as well as by our findings that the self-reported use of class rank is significantly associated with use of prescription nootropic substances. Mental health may also play a role in stimulant susceptibility, with depression rates among medical students more than double rates seen in the general public (20% versus 8.7%).

Paramount in the discussion of stimulant use is the idea of medical safety as our study results indicate that often these substances are not being used in a best-practice fashion. A high proportion of students gave away or sold these restricted medications to others, indicating that individuals with true contraindications such as undiagnosed cardiac disease, hyperthyroidism, or mood disorders may be put at unnecessary risk. Additionally, use was significantly associated with use of recreational drugs.

Mounting literature supports the theory of short-term memory enhancement with prescription stimulant use. Similar to the example of steroids among professional athletes, drug-induced cognitive enhancement may be perceived as providing an unfair advantage to some students. While data suggests that amphetamines most benefit memory in individuals with average cognitive functioning, some users actually experience impairment in overall cognition. Some argue that the majority of individuals seeking these medications from physicians during college and medical school may have a legitimate medical reason, given that ADD is estimated to affect three to five percent of adults, and only 10% of affected individuals currently have a diagnosis. Certainly for those students, overall performance would be significantly diminished without the appropriate use of these drugs, and there should be caution to avoid stigmatizing them. However, many of these students endorsed being prescribed these stimulants without an
actual diagnosis, contrary to current FDA guidelines and proper medical practice. Although not assessed, it is likely that side effects are present among this population and may represent another relative contraindication to widespread use.

Psychoactive substance use among medical students represents an unstudied policy concern for the medical profession. In a recent, controversial article in Nature, Greely et al. advocated the use of cognitive enhancing drugs by individuals in occupations in which one person’s life is dependent upon another. Specifically, the authors targeted the medical profession, stating that it would be ethically sound to require surgeons to take a drug in order to “save more patients” (p. 703). With the controversy regarding work hour restrictions among residents, some have called for the use of a wakefulness-promoting stimulant, modafinil, as an alternative to reduced hospital hours to reduce residency-induced fatigue. As the policy making bodies in sports have done to regulate the use of performance enhancing substances, it may be time for the major professional organizations in medicine to do the same. A discussion amongst the AAMC (Association of American Medical Colleges), ACGME (Accreditation Council on Graduate Medical Education), ABMS (American Board of Medical Specialties) and FSMB (Federation of State Medical Boards) would be welcome to examine this issue of nootropic drug use amongst students, residents, and practicing physicians.

This study has several limitations. Given that student’s responses are self-reported and non-medically prescribed stimulant use is illegal, misreporting is a potential concern in this survey. However, the survey did not distinguish between giving away (illegal) or selling (criminal) these drugs. Previous studies have indicated that anonymous self-reported surveys have low misreporting rates. The response rate (41%), despite three email reminders, while
low, is considered adequate for a web-based survey\textsuperscript{38}. Our data included sampling of students only in the Chicago area, impacting our ability to generalize about students in other geographic regions or in nonurban settings. However, the individuals who responded are representative of the overall student population at each school and likely provide good representation of the total medical student population in this geographic area.

This study improves our understanding of nootropic drug use among medical students. Future studies should examine the prevalence and correlates of nootropic use among students in other medical schools, residents and practicing physicians. Monitoring performance under the influence of these substances, in simulations and even in actual patient care, is indicated. There is a growing need for evidence-based policy making among this special population.

Acknowledgements:

The authors wish to thank Marina Wolf, Ph.D., Department of Neuroscience, Rosalind Franklin University of Medicine and Science, for her contributions to the study conception and to manuscript preparation, and Holly Geyer, M.D., Department of Internal Medicine, Mayo Clinic, for her contributions to the study conception.

Funding was provided with support from Rosalind Franklin University of Medicine and Science.
Robyn M. Emanuel, M.D., MPH has no conflicts of interest to report.

Sandra Frellsen, MD has no conflicts of interest to report.

Kathleen Kashima, PhD has no conflicts of interest to report.

Sandra M. Sanguino, MD, MPH has no conflicts of interest to report.

Frederick S. Sierles, MD has no conflicts of interest to report.

Cathy J. Lazarus, MD, FACP has no conflicts of interest to report.

Ethical approval has been granted for this study from Institutional Review Boards of all participating schools.

Disclaimer: none

Previous Presentations: none

The contents of this article do not represent the views of the Department of Veterans Affairs or the United States Government.

A copy of the questionnaire is available from the corresponding author (clazaru@tulane.edu)
References:


Table 1. Moderate-to-strong correlations among variables significantly associated with in drug use among medical students.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Pearson’s $r$</th>
<th>Significance ($p$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Psychostimulants consumed in the past 30 days by…</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barbiturates consumed in the past year</td>
<td>.488</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Ecstasy consumed in the past year</td>
<td>.439</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Tranquilizers consumed in the past year</td>
<td>.365</td>
<td>.001</td>
</tr>
<tr>
<td>Psychostimulants used in the past 12 months</td>
<td>.684</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Psychostimulants used in one’s lifetime</td>
<td>.576</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Marijuana consumed in the past year by…</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LSD or other psychedelics consumed in the past year</td>
<td>.382</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Alcohol consumed in a typical week by…</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LSD or other psychedelics consumed in the past year</td>
<td>.95</td>
<td>.002</td>
</tr>
</tbody>
</table>
**Figure 1.** Source of psychostimulant acquisition among medical students who have used psychostimulants (n=184).

<table>
<thead>
<tr>
<th>Source</th>
<th>Count</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friend or Relative</td>
<td>96</td>
<td>48.5%</td>
</tr>
<tr>
<td>Psychiatrist</td>
<td>48</td>
<td>24.2%</td>
</tr>
<tr>
<td>Classmate</td>
<td>47</td>
<td>23.7%</td>
</tr>
<tr>
<td>Primary care practitioner</td>
<td>33</td>
<td>16.7%</td>
</tr>
<tr>
<td>Acquaintance</td>
<td>26</td>
<td>13.1%</td>
</tr>
<tr>
<td>Student health professional</td>
<td>4</td>
<td>2.0%</td>
</tr>
<tr>
<td>Internet</td>
<td>2</td>
<td>1.0%</td>
</tr>
<tr>
<td>Neurologist</td>
<td>1</td>
<td>0.5%</td>
</tr>
<tr>
<td>Faculty member</td>
<td>1</td>
<td>0.5%</td>
</tr>
</tbody>
</table>
**Figure 2.** Medical student reasons for psychostimulant use (n=186).

### Reasons for Use Among Lifetime Users

*(select option/open answer textual responses, n=186)*

<table>
<thead>
<tr>
<th>Reason</th>
<th>Count (Percentage)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Help me to study</td>
<td>129 (65.2%)</td>
</tr>
<tr>
<td>Help me concentrate</td>
<td>122 (61.6%)</td>
</tr>
<tr>
<td>Stay awake</td>
<td>72 (36.4%)</td>
</tr>
<tr>
<td>Increase my alertness</td>
<td>70 (35.4%)</td>
</tr>
<tr>
<td>Obtain better grades</td>
<td>61 (30.8%)</td>
</tr>
<tr>
<td>Treat my ADD or ADHD</td>
<td>48 (24.2%)</td>
</tr>
<tr>
<td>Experiment</td>
<td>33 (16.7%)</td>
</tr>
<tr>
<td>Increase my enthusiasm</td>
<td>30 (15.2%)</td>
</tr>
<tr>
<td>Give me a high</td>
<td>26 (13.1%)</td>
</tr>
<tr>
<td>Increase my activity level</td>
<td>23 (11.6%)</td>
</tr>
<tr>
<td>Make me less apathetic</td>
<td>12 (6.1%)</td>
</tr>
<tr>
<td>Maintain a habit</td>
<td>7 (3.5%)</td>
</tr>
<tr>
<td>Other - open answer response</td>
<td>6 (3.0%)</td>
</tr>
<tr>
<td>Help me lose weight</td>
<td>6 (3.0%)</td>
</tr>
<tr>
<td>Decrease my activity level</td>
<td>5 (2.5%)</td>
</tr>
<tr>
<td>Counteract the effects of...</td>
<td>5 (2.5%)</td>
</tr>
<tr>
<td>Treat my narcolepsy</td>
<td>3 (1.5%)</td>
</tr>
</tbody>
</table>